This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GBT Global Blood Therapeutics (GBT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Global Blood Therapeutics Stock (NASDAQ:GBT) 30 days 90 days 365 days Advanced Chart Remove Ads Get GBT alerts:Sign Up Key Stats Today's Range$68.49▼$68.4950-Day Range$68.07▼$68.4952-Week Range$21.65▼$73.02Volume74 shsAverage Volume2.07 million shsMarket Capitalization$4.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Read More… Remove Ads Global Blood Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreGBT MarketRank™: Global Blood Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 914th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Global Blood Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.71) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlobal Blood Therapeutics has a P/B Ratio of 22.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GBT. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlobal Blood Therapeutics does not currently pay a dividend.Dividend GrowthGlobal Blood Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.95 Short InterestThere is no current short interest data available for GBT. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for GBT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Global Blood Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Global Blood Therapeutics is held by insiders.Read more about Global Blood Therapeutics' insider trading history. Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GBT Stock News HeadlinesAmex GBT Receives Credit Rating Upgrade; Moody’s Upgrades the Company to B1March 26, 2025 | finance.yahoo.comGaruda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell TherapiesMarch 4, 2025 | markets.businessinsider.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Amex GBT Labels DOJ Lawsuit to Block CWT Merger a ‘Blatant Politicized Effort’January 15, 2025 | msn.comGBT Technologies to acquire Nexus Workspaces from CGINovember 27, 2024 | seekingalpha.comLouisville men's basketball coach Pat Kelsey on 3-point shooting, bench depth and 'GBT'October 25, 2024 | sports.yahoo.comActivist investor Starboard forges $1bn stake in Pfizer to swing profitsOctober 7, 2024 | msn.comActivist investor Starboard Value takes $1 billion stake in Pfizer, sources sayOctober 7, 2024 | finance.yahoo.comSee More Headlines GBT Stock Analysis - Frequently Asked Questions How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.03. The firm's revenue was up 41.1% compared to the same quarter last year. When did Global Blood Therapeutics IPO? Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Meta Platforms (META), Intel (INTC), Bristol-Myers Squibb (BMY) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/04/2021Today4/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GBT CIK1629137 Webwww.gbt.com Phone(650) 741-7700FaxN/AEmployees457Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-303,090,000.00 Net Margins-137.30% Pretax Margin-137.01% Return on Equity-170.37% Return on Assets-39.24% Debt Debt-to-Equity Ratio4.92 Current Ratio6.88 Quick Ratio6.17 Sales & Book Value Annual Sales$194.75 million Price / Sales23.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book22.46Miscellaneous Outstanding Shares67,476,000Free Float64,170,000Market Cap$4.62 billion OptionableOptionable Beta0.45 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:GBT) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Blood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Blood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.